Los Angeles Capital Management LLC Decreases Position in Haemonetics Co. (NYSE:HAE)

Los Angeles Capital Management LLC reduced its stake in Haemonetics Co. (NYSE:HAE) by 51.7% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 25,638 shares of the medical instruments supplier’s stock after selling 27,420 shares during the period. Los Angeles Capital Management LLC owned 0.05% of Haemonetics worth $2,192,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Carmel Capital Partners LLC acquired a new stake in Haemonetics during the 3rd quarter worth $30,000. Group One Trading L.P. purchased a new position in shares of Haemonetics during the third quarter worth approximately $55,000. Parkside Financial Bank & Trust raised its position in Haemonetics by 17.4% in the 4th quarter. Parkside Financial Bank & Trust now owns 1,054 shares of the medical instruments supplier’s stock valued at $90,000 after purchasing an additional 156 shares during the last quarter. C M Bidwell & Associates Ltd. boosted its stake in Haemonetics by 19.7% during the 3rd quarter. C M Bidwell & Associates Ltd. now owns 2,389 shares of the medical instruments supplier’s stock worth $214,000 after purchasing an additional 393 shares during the period. Finally, DekaBank Deutsche Girozentrale grew its holdings in shares of Haemonetics by 172.8% during the third quarter. DekaBank Deutsche Girozentrale now owns 2,657 shares of the medical instruments supplier’s stock worth $239,000 after buying an additional 1,683 shares during the last quarter. Institutional investors and hedge funds own 99.67% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on HAE. StockNews.com cut Haemonetics from a “buy” rating to a “hold” rating in a research report on Friday, March 22nd. Barrington Research reaffirmed an “outperform” rating and set a $105.00 price target on shares of Haemonetics in a report on Friday, April 12th. Finally, TheStreet cut shares of Haemonetics from a “b-” rating to a “c+” rating in a research note on Thursday, February 29th.

Haemonetics Stock Up 1.0 %

HAE stock opened at $95.35 on Tuesday. The company has a quick ratio of 1.76, a current ratio of 2.92 and a debt-to-equity ratio of 0.91. The firm’s 50-day simple moving average is $82.81 and its 200 day simple moving average is $82.69. The stock has a market cap of $4.84 billion, a PE ratio of 38.76, a price-to-earnings-growth ratio of 2.23 and a beta of 0.34. Haemonetics Co. has a fifty-two week low of $70.74 and a fifty-two week high of $96.25.

Haemonetics (NYSE:HAE) last posted its quarterly earnings data on Thursday, February 8th. The medical instruments supplier reported $1.04 EPS for the quarter, topping analysts’ consensus estimates of $0.94 by $0.10. The company had revenue of $336.20 million for the quarter, compared to the consensus estimate of $320.84 million. Haemonetics had a return on equity of 22.37% and a net margin of 9.97%. The company’s quarterly revenue was up 10.1% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.85 EPS. As a group, sell-side analysts predict that Haemonetics Co. will post 3.95 EPS for the current year.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system, and Donor360.